Holen Sie sich die Stockscreener-App
31.37
2.40%
-0.77
Handel nachbörslich:
31.37
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com India
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity's Muscular Dystrophy Drug Del-brax Gets FDA Accelerated Approval Path: Key Data Coming - Stock Titan
Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq
Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus
Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus
Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus
RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus
Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada
BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Benzinga
Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - marketscreener.com
Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus
Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks
Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants - BioSpace
Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus
Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - marketscreener.com
Avidity reports promising FSHD therapy trial results - Investing.com
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - WV News
Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily
(RNA) Investment Analysis - news.stocktradersdaily.com
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider
Avidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA) - Defense World
Stifel Financial Corp Cuts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for RNA - Defense World
FY2025 EPS Estimates for RNA Lowered by Cantor Fitzgerald - Defense World
When (RNA) Moves Investors should Listen - news.stocktradersdaily.com
Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Avidity Biosciences Reports Q1 2025 Earnings - TipRanks
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $68.00 by Analysts at HC Wainwright - Defense World
Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald
Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Avidity Biosciences’ (RNA) Buy Rating Reiterated at Chardan Capital - Defense World
Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):